Key Insights on Gross Profit: United Therapeutics Corporation vs BioCryst Pharmaceuticals, Inc.

Biotech Giants: Profit Growth from 2014 to 2023

__timestampBioCryst Pharmaceuticals, Inc.United Therapeutics Corporation
Wednesday, January 1, 2014134860001162636000
Thursday, January 1, 2015463610001396725000
Friday, January 1, 2016236540001526100000
Sunday, January 1, 2017234840001619600000
Monday, January 1, 2018201820001429100000
Tuesday, January 1, 2019447340001331200000
Wednesday, January 1, 2020161360001375200000
Friday, January 1, 20211499060001563000000
Saturday, January 1, 20222642330001789600000
Sunday, January 1, 20233267510002070000000
Loading chart...

Unleashing the power of data

A Tale of Two Biotechs: Gross Profit Trends from 2014 to 2023

In the competitive landscape of biotechnology, United Therapeutics Corporation and BioCryst Pharmaceuticals, Inc. have showcased contrasting trajectories in gross profit over the past decade. From 2014 to 2023, United Therapeutics consistently outperformed, with gross profits peaking at approximately $2.07 billion in 2023, marking a 78% increase from 2014. In contrast, BioCryst Pharmaceuticals, while showing growth, reached a gross profit of $327 million in 2023, a significant leap from $13 million in 2014, reflecting a remarkable 2,300% increase.

This data highlights the dynamic nature of the biotech industry, where strategic innovation and market positioning can lead to substantial financial gains. As investors and stakeholders analyze these trends, the focus remains on how these companies will navigate future challenges and opportunities in the ever-evolving healthcare sector.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025